SHINVA(SH:600587) Sou Hu Cai Jing·2026-01-29 11:49Core Viewpoint - Xinhua Medical (600587) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 6.978 billion yuan, a year-on-year decrease of 6.0% [2]. - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 370 million yuan, a decline of 38.98% year-on-year [2]. - In Q3 2025, the single-quarter main revenue was 2.188 billion yuan, down 2.2% year-on-year [2]. - The single-quarter net profit attributable to shareholders was approximately 48.59 million yuan, a significant drop of 63.39% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was about 37.66 million yuan, down 71.77% year-on-year [2]. - The company's debt ratio stood at 45.85%, with investment income of 48.28 million yuan and financial expenses of 21.30 million yuan [2]. - The gross profit margin was reported at 25.11% [2]. Market Activity - As of January 29, 2026, Xinhua Medical's stock closed at 16.03 yuan, down 0.19%, with a turnover rate of 2.09% and a trading volume of 126,300 hands, amounting to a transaction value of 203 million yuan [1]. - On January 29, the net outflow of main funds was 4.74 million yuan, accounting for 2.34% of the total transaction value, while the net inflow of retail funds was 4.77 million yuan, also accounting for 2.35% [1]. - Retail investors experienced a net outflow of 27,400 yuan, representing 0.01% of the total transaction value [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions over the past 90 days is 20.0 yuan [3].